within Pharmacolibrary.Drugs.ATC.J;

model J01EB20
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>ATC code J01EB20 refers to combinations of short-acting sulfonamides, which are antibacterial agents primarily used in the past to treat urinary tract infections and other susceptible bacterial infections. Most sulfonamide combinations are not used widely today due to resistance and the development of newer antibiotics.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients receiving oral sulfonamide combinations (e.g., sulfadiazine + sulfamerazine), as scientific publications with explicit population PK models for these combinations are lacking.</p><h4>References</h4><ol><li><p>Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical pharmacokinetics</i> 55(4) 409–418. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0326-7&quot;>10.1007/s40262-015-0326-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26369775/&quot;>https://pubmed.ncbi.nlm.nih.gov/26369775</a></p></li><li><p>Kaufman, JL, et al., &amp; Kumar, S (2021). Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American journal of hematology</i> 96(4) 418–427. DOI:<a href=&quot;https://doi.org/10.1002/ajh.26083&quot;>10.1002/ajh.26083</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33368455/&quot;>https://pubmed.ncbi.nlm.nih.gov/33368455</a></p></li><li><p>Cockerill, FR, &amp; Edson, RS (1987). Trimethoprim-sulfamethoxazole. <i>Mayo Clinic proceedings</i> 62(10) 921–929. DOI:<a href=&quot;https://doi.org/10.1016/s0025-6196(12)65049-6&quot;>10.1016/s0025-6196(12)65049-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3498863/&quot;>https://pubmed.ncbi.nlm.nih.gov/3498863</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01EB20;
